A Michigan woman with motor neuron disease, who has difficulty speaking, became the first patient to receive Paradromics’ Connexus brain-computer interface during surgery at University of Michigan Health. The implantation marks the start of the FDA-approved Connect-One early feasibility study. She will be followed and evaluated over the next six years.

Paradromics, based in Austin, Texas, announced the surgery on 17 June 2026 through a Michigan Medicine institutional release and a corporate statement on BusinessWire. The Food and Drug Administration approved an Investigational Device Exemption for the study in November 2025, which Paradromics describes as the first IDE for speech restoration through a fully implantable BCI. Connect-One is multi-site, with the University of Michigan, the University of California Davis, and Massachusetts General Hospital all screening eligible participants.

How the device works

The Connexus system has three components. An implantable high-density microelectrode array sits on the cortex and records neural activity. The recorded data flows to a discrete transceiver implanted in the patient’s chest, which transmits the signal wirelessly through the skin to an external receiver. Software then translates the neural signals into communication output, with the initial clinical focus on restoring independent speech and on enabling computer control through brain activity. The device targets people with severe motor impairment from spinal cord injury, stroke, or motor neuron diseases including ALS.

The surgical team

The procedure was performed by Matthew Willsey, MD, PhD, a neurosurgeon and biomedical engineer at the University of Michigan, with Aditya S. Pandey, MD, and a multidisciplinary team of providers. Willsey’s group had previously demonstrated that the Connexus device could be safely implanted in a human, record brain signals, and be removed intact in less than 20 minutes. The Lead Principal Investigator for the Connect-One study is David M. Brandman, MD, associate professor of neurosurgery at UC Davis. Brandman is also co-senior author and co-principal investigator (with Sergey Stavisky) on the Casey Harrell ALS speech-BCI paper published in Nature Medicine on 15 June 2026 (lead author Nicholas Card), which documented 22.6 months and more than 3,800 hours of at-home use of a separate intracortical speech BCI.

What the study is testing

Connect-One will evaluate long-term use of the Connexus BCI for two clinical purposes: safely restoring speech and enabling computer control for people with severe motor impairment. The first participant has been enrolled. The six-year evaluation horizon reflects the safety and durability questions that have defined the speech-BCI field over the past three years. Brain-computer interfaces typically face two failure modes in long-term implantation: signal drift as scar tissue forms around the electrodes, and brain degeneration in patients with progressive disease. The company’s BusinessWire statement does not specify the safety and signal stability endpoints the study will report at each evaluation window.

Where this places Paradromics in the field

Paradromics has been one of the most closely watched clinical-stage BCI companies for several years, alongside Neuralink, Synchron, and Precision Neuroscience. The Connect-One first implantation moves Paradromics from preclinical and intraoperative work into a long-term human-implantation cohort. Neuralink has implanted more than twenty patients and is pushing toward high-volume production through 2026. Synchron is preparing its 2026 pivotal trial run-up. Precision Neuroscience is operating its Layer 7 cortical interface in patients. The clinical-stage BCI cohort is now at the point where multiple companies are running at-home or in-life implantation studies in parallel, which is a different operational picture from the trial-only landscape of even two years ago.

Comment from the company

Matt Angle, Paradromics chief executive officer and founder, called the implantation “a major milestone for Paradromics and for the future of high-performance brain-computer interfaces” in the company’s announcement. “For people living with severe motor impairment, the ability to communicate is central to agency, identity, and connection. We are honored to begin this clinical study with our first participant and grateful for the trust she and the clinical team have placed in us,” Angle said. David Brandman, the Lead Principal Investigator, added that the Connexus BCI “reflects decades of progress across the intracortical BCI research community” and that the Connect-One Study gives the field the opportunity to evaluate that progress in a rigorous clinical setting.

What to watch next

Paradromics has not disclosed a timeline for additional implantations in the Connect-One study. The next milestones for the field to track are the first speech-decoder activation in the implanted participant, any safety readouts from the multi-site cohort, and Paradromics’ decisions on which additional patient subgroups (spinal cord injury, stroke, ALS) it enrolls first.

Sources

• Paradromics and University of Michigan Complete First Connexus® BCI Implantation for the FDA-Approved Connect-One Clinical Study (BusinessWire, 17 June 2026)
• University of Michigan implants first-in-human Paradromics wireless BCI (Michigan Medicine)
• Paradromics completes first implant in BCI early feasibility study (MassDevice, 17 June 2026)
• Neuralink Rival Paradromics Says First Brain-Chip Device Was Implanted (Business Insider)
• University of Michigan Achieves First Human Implantation of Paradromics Wireless BCI (Bioengineer.org)
• Paradromics implants brain chip in its first patient (TheNextWeb)